Background {#Sec1}
==========

Acute myeloid leukemia (AML) is a highly heterogeneous disease, for which precise diagnosis and risk stratification is crucial. Currently the best diagnostic methods for AML include morphologic, flow cytometric, cytogenetic and molecular examination (sometimes bone marrow biopsy is also needed). A combination of these examinations presents a relatively comprehensive understanding of the disease \[[@CR1], [@CR2]\]. On the other hand, discovering new biomarkers associated with prognosis and exploring their relationship with clinical outcomes have become the focus of researches. In addition to pre-treatment information, some types of post-treatment information, such as minimal residual disease (MRD) \[[@CR3], [@CR4]\], response to first induction chemotherapy \[[@CR5]\], and repeated bone marrow examination (morphologic, cytogenetic, flow cytometric, or molecular) during or after treatment courses \[[@CR6]--[@CR8]\] are also reported to be informative. As the embodiment of "real response" to standard therapy, post-treatment data should be carefully considered. It is a necessary complement for prognosis evaluation. For example, although more than 50% of newly diagnosed AML patients will achieve CR after standard induction chemotherapy, a large proportion of them will relapse and eventually die after different durations of CR \[[@CR9]\]. Thus, the predictive factor of this difference among CR patients should be further identified. In this study, patients achieving MRD-negative CR were included. We calculated the platelet count changes between 'before treatment' and 'after achieving the first MRD-negative CR' (D~PLT~) for each patient, and explored whether or not this platelet change is potentially predictive of progression-free survival (PFS) or overall survival (OS) in these patients.

Methods {#Sec2}
=======

Patients and methods {#Sec3}
--------------------

A total of 105 patients newly diagnosed with AML (M3 and myeloid sarcoma excluded) in the Sun Yat-sen University Cancer Center from 2002.10 to 2016.12 were enrolled in this study. The diagnosis was based on the 2002 World Health Organization (WHO) criteria \[[@CR10]\]. All patients received standard induction chemotherapy containing cytarabine and DNR/IDR (DNR 50 mg/m^2^, d1--3 + Ara-C 100 mg/m^2^, d1--7; or IDA 12 mg/m^2^, d1--3 + Ara-C 100 mg/m^2^, d1--7). Among the 105 patients, 38 never achieved MRD-negative CR or died of complications in induction chemotherapy courses, while the other 67 obtained MRD-negative CR after one, two or three courses of induction therapy. MRD was detected with multiparametric flow cytometry (MFC) \[[@CR7]\]. The sensitivity of the MRD assay was 0.01%. All patients who achieved MRD-negative CR also met the criteria of the widely used morphological definition of CR: the presence of \< 5% blasts in the bone marrow, the absence of extramedullary disorders, the recovery of neutrophil counts \> 1 × 10^9^/L, and the platelet count \> 100 × 10^9^/L in the peripheral blood. All of these 67 patients then acquired consolidation therapy, among whom 32 received JALSG AML-201 regimen \[[@CR11]\], 24 received AML-87 regimen \[[@CR12]\], and 11 received High Dose Ara-C regimen \[[@CR13]\]. After consolidation therapy was accomplished, follow-up was conducted and prognostic information (PFS and OS) was obtained. This study was approved by the Ethical committee of Sun Yat-sen University Cancer Center. Informed consent was obtained from all individual patients included in the study. All experiments were performed in accordance with the ethical standards of Declaration of Helsinki.

For each of the 67 MRD-negative CR patient, we measured peripheral platelet count on the day before initial treatment (denoted as PLT~pre~), and platelet peak value after marrow recovery following the chemotherapy course that induced the first MRD-negative CR (denoted as PLT~peak~). PLT~peak~ appeared during 28--35 days from the first day of the chemotherapy course in all enrolled patients. Then the difference (denoted as D~PLT~) between these two values (D~PLT~ = PLT~peak~ − PLT~pre~) was calculated. Based on corresponding survival data, we searched for an optimal cut-point of D~PLT~ by x-tile software (Version: 3.6.1, Copyright Yale University 2003--05) \[[@CR14], [@CR15]\] to further distinguish prognosis. To avoid statistical bias introduced by 'multiple cut-off selection', a cross validation was conducted to test the robustness of the established cut-point \[[@CR16], [@CR17]\] (See 'Result' part and Fig. [1](#Fig1){ref-type="fig"}). Fig. 1X-tile analysis of survival data of 67 included patients. Every pixel of the plot represents the χ^2^ log-rank value generated from corresponding division of the data. Direct associations between D~PLT~ and survival (higher D~PLT~ indicates a better outcome) are colored green, whereas indirect associations (higher D~PLT~ indicates poorer outcome) are colored red. A brighter (green or red) pixel color represents a larger χ^2^ log-rank value and a stronger association. **a.** Determination of the optimal cut-point. Survival data used for cut-point optimization is PFS. The optimal cut-point (D~PLT~ = 212 × 10^9^/L) appears at the brightest pixel (The black dot on the straight line below). **b.** A histogram showing the distribution of the entire cohort and the established cut-point. **c.** Kaplan-Meier curve of PFS between high and low D~PLT~ groups. The cutoff value is D~PLT~ = 212 × 10^9^/L. A significantly better PFS is observed in high D~PLT~ group (*p*-value given by cross-validation is 0.016. The blue line represents for low D~PLT~ group while the gray line represents for high D~PLT~ group) **d**. Kaplan-Meier curve of OS between high and low D~PLT~ groups. The cutoff value is D~PLT~ = 212 × 10^9^/L. A better OS is observed in high D~PLT~ group, but without significance (*p* value given by cross validation is 0.106. The blue line represents for low D~PLT~ group and the gray line represents for high D~PLT~ group)

Among the 67 patients, single-course-CR patients (43 cases) were expected to have less marrow function impairment than multiple-course-CR patients (24 cases). We compared the mean of D~PLT~ and PLT~peak~ between the two groups. As we included patients needing 1 to 3 cycles to achieve MRD-negative CR in our study, we first tested whether or not there was significant difference of prognosis between single and multiple-course-CR patients. Secondly, we isolated the 43 single-course-CR patients and determine the optimal cut-point of D~PLT~ by,the same method as above. We compared the predictive strength of D~PLT~ and the number of courses to achieve CR.

After establishing the cut-point, survival analysis was conducted to test whether there is significant difference of PFS or OS between high and low D~PLT~ groups, and whether D~PLT~ is an independent indicator for AML prognosis.

Survival analysis {#Sec4}
-----------------

PFS is defined as the time from the date of achieving the first MRD-negative CR to the date of relapse or death (with no definite record of relapse). OS is defined as the time from the date of achieving the first MRD-negative CR to the date of death. The optimal cut-point of D~PLT~ was established by x-tile software (Version: 3.6.1, Copyright Yale University 2003--05), then a cross validation analysis as reported by Faraggi and Simon \[[@CR17]\] was applied to test its significance. Specifically, a two-folded cross-validation was conducted. The whole dataset was randomly split into two subsets with equal size (Subset A and B). In subset A, we searched for the cutoff value with minimal two-sided log-rank *p*-value. Using this value, we divided subset B into two groups ('above cut-point' group and 'below cut-point' group). Similarly, in subset B we searched for the cutoff value with minimal two-sided log-rank *p*-value, and divided subset A into 'above cut-point' group and 'below cut-point' group according to this value. Now every patient in the whole dataset was assigned into either 'above cut-point' group or 'below cut-point' group. Then the log-rank Chi-square value and corresponding *p*-value stratified by subset A and B was calculated to test the significance of the established cut-point.

Based on the cut-point, the 67 patients were divided into 2 subgroups (high-D~PLT~ and low-D~PLT~). Categorical baseline features of the two subgroups were compared using χ^2^ test/Pearson chi-square test, whereas numerical ones were compared using a non-parametric Mann-Whitney U-test. Survival data was analyzed with Kaplan--Meier methodology, and the differences between groups were evaluated with a log-rank test. Cox multivariate regression analysis was used to test whether or not D~PLT~ is an independent predictor of PFS or OS after considering some potential prognostic covariates, including gender, age, cytogenetic risk, the number of chemotherapy courses needed to achieve MRD-negative CR, and consolidation regimen.

Results {#Sec5}
=======

Patient characteristics {#Sec6}
-----------------------

Clinical and laboratory information of the 67 included patients at diagnosis is shown in Table [1](#Tab1){ref-type="table"}. Among the 67 patients, 33 were male, and 34 were female. Median age at diagnosis was 40.0 years (range of 3--69 years). According to 2016 WHO diagnosis and risk stratification system of AML \[[@CR2]\], 12 patients were classified as favorable cytogenetics, 13 as adverse cytogenetics, and the remaining 42 as intermediate risk. At the time of diagnosis, median WBC count was 21.2 X 10^9^/L (range of 0.7--296.4), median hemoglobin level was 77 g/L (range of 39--144), and median platelet level was 43 X 10^9^/L (range of 3--282) (Table [1](#Tab1){ref-type="table"}). Forty-three patients achieved MRD-negative CR after 1 course of induction therapy, twenty-one after 2 courses, and three after 3 courses. During marrow recovery after the chemotherapy course that induced the first MRD-negative CR, median platelet peak value (PLT~peak~) was 389 X 10^9^/L (range of 122--984), and median D~PLT~ was 328 X 10^9^/L (range of 86--981) (Table [1](#Tab1){ref-type="table"}). Mean follow-up time was 29 months (range of 5--90 months). Two-year PFS and OS rates of all the 67 patients were 48.1 and 63.5%, respectively. Three-year PFS and OS rates were 40.6 and 57.4%, respectively. Table 1Clinical characteristics and laboratory test data of the 67 patients achieving MRD-negative CRCharacteristicsAge (year) Median40.0 Range3--69Sex Male33 Female34Initial White cell count (10^9^/L) Median21.2 Range0.7--296.4Initial Hemoglobin (g/L) Median77.0 Range39--144Initial Platelet Count (10^9^/L) Median43.0 Range3--282Bone Marrow Blasts (%) Median66.5 Range22.9--98Risk Group (No.) Favorable12 Intermediate42 Adverse13Courses needed to achieve MRD-negative CR 143 221 33Consolidation Regimen AML-20132 AML-8724 HDAra-C11Peak Platelet Count (PLT~peak~,10^9^/L) Median389. Range122--984D~PLT~ (10^9^/L) Median328 Range86--981

Prognosis analysis for survival {#Sec7}
-------------------------------

Notice that there are two available survival datasets for determination of the optimal cut-point: PFS and OS. For PFS, the optimal cut-point is D~PLT~ = 212 × 10^9^/L (statistically significant, Chi-square value is 5.833, and *p*-value is 0.016 given by cross validation), while for OS no cut-point with statistical significance was found (p-value is 0.106) (See Fig. [1](#Fig1){ref-type="fig"}). We then choose the cut-point as D~PLT~ = 212 × 10^9^/L for following analysis. Based on this value, all the 67 patients were divided into high and low D~PLT~ groups. The characteristics of patients in these two subgroups are shown in Table [2](#Tab2){ref-type="table"}. No significant difference was observed between the two subgroups in terms of distribution of gender, age, cytogenetic risk, consolidation regimen, and the number of chemotherapy courses needed to achieve MRD-negative CR. Table 2Clinical characteristics and laboratory test data of patients in high D~PLT~ group and low D~PLT~ group (Cutoff value: D~PLT~ = 212 × 10^9^/L)CharacteristicsHigh D~**PLT**~ Group\
(*n* = 52)Low D~**PLT**~ Group\
(*n* = 15)***p*** valueAge (year) Median38.542.00.144 Range3--6920--67Sex Male2490.345 Female286Initial White cell count (10^9^/L) Median18.345.30.299 Range0.7--296.411.04--149Risk Group (No.) Favorable1020.870 Intermediate3210 Adverse103Courses needed to achieve MRD-negative CR 13670.092 2156 312Consolidation Regimen AML-871860.783 AML-201266 HD Ara-C83

We found that patients in high D~PLT~ group had significantly better PFS (2-year PFS rate 56.3% versus 22.2%, 3-year PFS rate 49.7% versus 11.1%; cross validation *p*-value = 0.016.) and better OS, although without statistical significance (2-year OS rate 68.5% versus 45.9%, 3-year OS rate 60.9% versus 45.9%; cross validation p-value = 0.106) (Fig. [1](#Fig1){ref-type="fig"}c and d).

Furthermore, by conducting a multivariate analysis of PFS and OS, we found that high D~PLT~ is an independent predictor of better prognosis. For PFS, HR = 2.894, 95% confidence interval 1.320--6.345, *p* = 0.008. For OS, the variables were HR = 3.077, 95% confidence interval: 1.130--8.376, *p* = 0.028 (See Table [3](#Tab3){ref-type="table"}). Table 3Results of analysis of risk factors for PFS and OSFactorsPFSOSunivariatemultivariateUnivariatemultivariateHR(95%CI)*P* valueHR(95%CI)*P* valueHR(95%CI)*P* valueHR(95%CI)*P* value**Age(As a numerical variate)**1.013(0.991--1.036)0.2471.008(0.982--1.034)0.5591.011(0.984--1.038)0.4290.998(0.969--1.027)0.871**SexMale**1.280(0.630--2.598)0.4951.207(0.560--2.599)0.6311.625(0.678--3.897)0.2771.545(0.594--4.016)0.372**Female**1.00--1.00--1.00--1.00--**Cytogenetics and Molecular RiskFavorable**1.00--1.00--1.00--1.00--**Intermediate**1.459(0.501--4.252)0.4891.573(0.469--5.280)0.4634.190(0.555--31.654)0.1652.743(0.294--25.590)0.376**Adverse**1.538(0.433--5.462)0.5061.809(0.484--6.768)0.3794.011(0.446--36.050)0.2156.744(0.676--67.256)0.104**Number of Induction Therapy Courses to achieve MRD-negative CR1**1.00--1.00--1.00--1.00--**More than 1**0.743(0.359--1.539)0.4240.655(0.286--1.498)0.3160.686(0.284--1.660)0.4040.494(0.188--1.295)0.151**Consolidation RegimenAML-87**0.798(0.320--1.987)0.6271.019(0.318--3.266)0.9751.274(0.414--3.921)0.6731.858(0.441--7.820)0.398**AML-201**0.652(0.252--1.687)0.3770.892(0.320--2.488)0.8270.372(0.093--1.493)0.1630.374(0.088--1.592)0.183**HDAra-C**1.00--1.00--1.00--1.00--**D**~**PLT**~**Hlgh**1.00--1.00--1.00--1.00--**Low**3.106(1.509--6.394)0.0022.894(1.320--6.345)0.0082.525(1.056--6.035)0.0373.077(1.130--8.376).0.028

Comparative analysis of single-course-CR and multiple-course-CR patients {#Sec8}
------------------------------------------------------------------------

In our study, 43 single-course-CR patients and 24 multiple-course-CR patients were included. No significant difference was found in platelet counts before treatment initiation (*p*-value = 0.663). According to our data, patients achieving MRD-negative CR with 1 course had a significantly higher platelet peak value (PLT~peak~) as well as platelet difference (D~PLT~) compared to patients with more courses. For single-course-CR patients D~PLT~ = (388.0 ± 176.3) × 10^9^/L, while for multiple-course-CR patients D~PLT~ = (300.6 ± 153.5) × 10^9^/L (*p*-value = 0.046). For single-course-CR patients PLT~peak~ = (456.4 ± 161.5) × 10^9^/L, while for multiple-course-CR patients PLT~peak~ = (358.0 ± 165.6) × 10^9^/L (p-value = 0.021). However, no significant difference of PFS or OS was observed between the two groups by Kaplan-Meier method. (*p* = 0.322 for PFS and *p* = 0.309 for OS) .

Next, to clarify if these differences also manifest in differential treatment outcome, we isolated the 43 single-course-CR patients, and searched for an optimal cut-point by x-tile software in this subgroup of patients. Among the 43 single-course-CR patients no statistically significant cut-point was found (*p*-value given by cross validation is 0.157 for PFS and 0.312 for OS). Because significant difference of clinical outcomes was found between high- and low-D~PLT~ subgroups rather than single- and multiple-course-CR subgroups, and there was no evidence for a different distribution of induction course number between high- and low-D~PLT~ subgroups, we speculate that the number of induction cycles to achieve CR is less informative than our new index D~PLT~ concerning AML prognosis.

Discussion {#Sec9}
==========

A whole set of diagnostic methods, including at least morphologic, flow cytometric, cytogenetic, and molecular examination, is necessary to make a precise diagnosis for AML. Pre-treatment information from patients is undoubtedly the footstone to form an overview of the disease and select the proper way of treatment. On the other hand, post-treatment information, such as MRD, can be regarded as "true response" rather than "prediction." These data helps to adjust the treatment plan according to the real condition of patients \[[@CR18], [@CR19]\]. Some related concepts, such as clonal evolution \[[@CR20]\], have provided the most profound understanding of the disease. Thus, post-treatment information and instant changes during treatment should be carefully considered. This study focused on post-treatment information.

Some previous studies reported that high blood cell counts after CR (morphological definition) are predictive of longer PFS and OS \[[@CR21], [@CR22]\]. In the current study, we strictly selected patients who achieved MRD-negative CR, and examined whether or not a high level of platelet recovery is still predictive of a better prognosis under such a stricter criterion of CR. We speculate that CR is possibly a continuous process with different degrees rather than an "either--or" question. Degree of CR is a reasonable powerful predictor of PFS and OS, which importance should be noted. However, accurate measurement of it is still inaccessible due to limitations of existing methodologies.

In our study, both single-course-CR and multiple-course-CR patients were included, among whom single-course-CR patients had significantly higher PLT~peak~ and D~PLT~ levels. However, survival analysis by Kaplan-Meier method showed no significant difference of PFS or OS between these two subgroups. According to our data, the number of courses to achieve CR is a minor factor of influence, which by itself is not sufficient to distinguish differential clinical outcomes. In contrast, significant difference emerges when we choose D~PLT~ as the prognosis indicator. D~PLT~ appears to be able to stratify for differences in treatment outcome and therefore have prognostic value, whereas the number of induction cycles is less informative in comparison.

To select patients with MRD-negative CR, we had to apply stringent selection criteria, which limited the number of patients included in this study. As a result, some constraints of this study merit attention. Firstly, the size of each group is relatively small, thereby restricting the choice of study designs. An independent validation cohort is absent to test the robustness of the established cut-point. Secondly, the study is retrospectively designed. Our findings require further evaluation and confirmation in a larger-scale prospective study with independent testing and validation cohorts. However, our study provides a clear basis for further investigations of post-treatment response biomarkers.

The underlying mechanism of this phenomenon needs further exploration. Researchers found that marrow failure in AML patients is probably due to a differentiation block impeding hematopoietic stem cells in the leukemic marrow to produce sufficient progenitors, rather than the depletion of hematopoietic stem cells \[[@CR23], [@CR24]\]. Many existing studies have also reported the effect of leukemic microenvironment to promote leukemic cell proliferation and survival, and to suppress normal hematopoiesis \[[@CR25]--[@CR27]\]. In addition, AML patients with CRp (complete remission with platelet count \< 100 × 10^9^/L) or CRi (complete remission with absolute neutrophil count \< 1.0 × 10^9^/L) are observed to have higher MRD levels and poorer outcomes \[[@CR3]\]. Based on these findings, we speculate that the degree of platelet count recovery (D~PLT~) may reflect the degree of remission and the improvement of the bone marrow microenvironment for normal hematopoiesis. This view is further supported by our observation that the signal for PFS is stronger compared to OS, suggesting better treatment response, but no ultimate cure (OS is influenced by more factors besides remission degree).

In previous studies, the platelet peak value after CR, similar to PLT~peak~ in our study, is the main study index. Here we chose D~PLT~ as the prognostic indicator of clinical outcomes. We also explored the relationship between PLT~peak~ and PFS/OS for comparison. Again patients in high PLT~peak~ group were found to have a better PFS and a better OS, but without statistical significance by cross validation. Our results showed that D~PLT~ rather than PLT~peak~ stratify differences of clinical outcomes better, especially for PFS. D~PLT~ seems a better prognosis indicator than PLT~peak~ alone. Theoretically, by calculating the difference of platelet count between "before treatment" and "after CR" of the same patient, D~PLT~ may at least partly reduce the bias caused by individual difference in overall platelet counts.

In this study, we determined the cut-point as D~PLT~ = 212 × 10^9^/L and test its significance by a cross validation analysis. We want to emphasize that the optimal cut-point cannot be easily determined. Peripheral blood counts are influenced by many factors; hence, the normal platelet level of the patients before suffering from AML (though difficult to get) may also be valuable. Whether or not a positive correlation exists between platelet recovery degree and remission degree still remains unclear. Further exploration and careful clinical observation are needed to discover the true biological meaning of this phenomenon.

Conclusions {#Sec10}
===========

This study demonstrated that the degree of platelet recovery after achieving the first MRD-negative CR (D~PLT~) is a potential predictor of clinical outcomes, especially for PFS, in CR patients. Higher D~PLT~ value is associated with longer PFS and OS. Our findings may help to develop simple methods for AML prognosis evaluation, although larger-scale prospective studies with independent testing and validation cohorts are required to further test our results.

AML

:   Acute myeloid leukemia

MRD

:   Minimal residual disease

CR

:   Complete remission

PFS

:   Progression free survival

OS

:   Overall survival

PLT~pre~

:   Peripheral platelet counts before initial treatment

PLT~peak~

:   Peripheral platelet peak value after marrow recovery following the chemotherapy course inducing the first MRD-negative CR

D~PLT~

:   Difference between PLT~peak~ and PLT~pre~

MFC

:   Multiparametric flow cytometry

CRi

:   Complete remission with absolute neutrophil count \< 1.0 × 10^9^/L

CRp

:   Complete remission with platelet count \< 100 × 10^9^/L

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yang Wang and Hua Wang contributed equally to this work.

Thanks the medical workers in Sun Yat-sen University Cancer Center for their management and care of the patients, and obtainment of the clinical data.

YW collected and analyzed the patient data and wrote the manuscript. HW and WW analyzed the data and wrote the manuscript. WL, NL and SL performed marrow aspiration, collected the data and wrote the manuscript. YL designed the study and wrote the manuscript. All authors read and approved the final manuscript.

Our work was funded by the following funds:

1\. National Natural Science Foundation of China, and the contract/grant number is 30471976 and 81272620.

2\. Science and technology projects of Guangdong Province, and the contract/grant number is 2016A020215086.

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethical committee of the Sun Yat-sen University Cancer Center and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Written informed consent was obtained from all individual patients included in the study. This study was approved by the Ethical committee of the Sun Yat-sen University Cancer Center.

Not applicable.

Our work was funded by the following funds:

1\. National Natural Science Foundation of China, and the contract/grant number is 30471976 and 81272620.

2\. Science and technology projects of Guangdong Province, and the contract/grant number is 2016A020215086.

One of the authors, Hua Wang, is a member of the editorial board of BMC Cancer.
